Ardelyx, Inc. (ARDX) stock

ARDXNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 9/3059% below fair value

$3.09−0.03 (-0.96%)

Close on Nov 13, 2026Market cap $769.99MP/E –Yield –

Ardelyx EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Ardelyx's EV/EBITDA was 165.1× on Oct 30, 2015.

Period	Period end	Value	Change (pts)
2015	Oct 30, 2015	165.1×	+43.6
2014	Dec 31, 2014	121.4×	–

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is ARDX.

Revenue growth16.8% · median 38.4%

Gross margin94.4% · median 87.4%

Operating margin-7.9% · median -15.7%

Net margin-12.4% · median -18.7%

Advertisement
300 × 250

See a number that looks wrong?